Myriad gets $14.2 million for pathogen drug/diagnostic:
This article was originally published in Clinica
Executive Summary
Myriad Genetics has been awarded a five-year, $14.2m contract by the US National Institutes of Health for work that could lead to the development of products that focus on microorganisms and pathogens. The Salt Lake City, Utah firm says it will use its expertise to characterise pathogen-host protein interactions in an effort to discover targets for the next generation of vaccines, therapeutics and diagnostics. Protein interaction and validation data will be made available to the research and development community through the Proteomics Research Program Administrative Center. Myriad says it retains the rights to commercialise diagnostic and therapeutic targets discovered from the project.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.